The media database brings together all published information on platforms and products, as well as financial and corporate news.
Join our mailing list.
06/09/2017
“Preclinical Efficacy of a Stable Aqueous Formulation of Human Glucagon with BioChaperone® Technology (BC GLU)” (Poster 1150), presented by Dr Grégory Meiffren, 77th Scientific Sessions of the American Diabetes Association, 9-13 June 2017 in San Diego, CA (USA)
06/09/2017
“Profil pharmacodynamique de BioChaperone® Combo, une co-formulation liquide des insulines lispro et glargine, chez des sujets diabétiques de type 2” (Abstract CAD-19), presented by Dr. Martin Gaudier, 2017, Société Francophone du Diabète (France)
06/09/2017
“L’insuline ultra-rapide BioChaperone® Lispro améliore le contrôle glycémique postprandial par rapport à Humalog® chez des sujets diabétiques de type 1” (Abstract CAD-19), presented by Dr. Grégory Meiffren, 2017, Société Francophone du Diabète (France)
06/09/2017
“BioChaperone® Combo, une co-formulation liquide des insulines lispro et glargine, présente un contrôle glycémique amélioré par rapport à un premix d’insuline.” (Abstract CAD-19), presented by Dr. Claire Megret, 2017, Société Francophone du Diabète (France)
06/07/2017
Adocia Initiates a Phase 1b Clinical Study on the Dose-Proportionality of BioChaperone® Combo in People with Type 2 Diabetes
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
06/06/2017
Adocia Announces Positive Topline Results from a Meal-Test Clinical Study of BioChaperone® Combo in People with Type 2 Diabetes
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
06/01/2017
Adocia initiates a study comparing ultra-rapid insulin BioChaperone® Lispro U100 with Fiasp® and Novolog® administered with an insulin pump
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
05/30/2017
Adocia Announces Six Data Presentations at the American Diabetes Association® 77th Scientific Sessions
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
04/18/2017
Adocia announces the release of its Reference Document, containing the Annual Financial Report and the Management Report, for the year 2016
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
01/27/2017
Adocia announces the termination by Eli Lilly of the collaboration on BioChaperone Lispro
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
01/19/2017
Adocia announces the transformation of its business model to increase the value of its projects
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
01/06/2017
Half year report on Adocia’s liquidity agreement with Kepler Chevreux
01/05/2017
Adocia announces two new multi-hormonal combination projects for the treatment of type 1 diabetes
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
12/16/2016
Adocia and Lilly announce successful completion of an insulin pump study with BioChaperone Lispro
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
11/07/2016
Adocia receives the 1st prize for ‘Profitable Growth’ and the 3rd ‘Technology Fast 50’ prize as part of the 2016 Deloitte In Extenso Technology Fast 50 Grand Rhône Alpes
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
10/27/2016
Adocia Announces Positive Topline Results from a Phase 1b Clinical Trial Measuring the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
09/20/2016
Adocia launches a new clinical study of BioChaperone® Combo, its combination of long-acting insulin glargine and fast-acting insulin lispro, in people with type 2 diabetes
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
09/19/2016
Adocia to hold conference call for investors to provide business update and growth perspectives Wednesday September 21st, 2016 at 6 PM (CET)
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
09/15/2016
BioChaperone® Combo, a co-formulation of lispro and glargine, demonstrates both prandial and basal insulin time-action profiles in a single injection in type 2 diabetes, Dr. S. Bruce, 52nd European Association for the Study of Diabetes (EASD) Annual Meeting, 12–16 September 2016, Munich (Germany)
09/15/2016
“BioChaperone® Combo (BC Combo) reduces post-prandial glucose in type 1 diabetes compared to conventional lispro mix 75/25 (LMx)” (Poster 836), presented by Dr. S. Bruce, 52nd European Association for the Study of Diabetes (EASD) Annual Meeting, 12–16 September 2016, Munich (Germany)
09/08/2016
Adocia to Present Clinical Data Validating BioChaperone® Technology at the 2016 EASD Annual Meeting
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
08/25/2016
Adocia announces topline results of Indian Phase 3 trial of BioChaperone PDGF for diabetic foot ulcer
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
06/11/2016
“A Pilot Bioequivalence (BE) Study of Ultra-Rapid Concentrated BioChaperone® Lispro (BCLIS) U200 to BCLIS U100”, (Abstract 2242-PUB), presented by Dr. Grit Anderson, 76th Scientific Sessions of the American Diabetes Association, 10-14 June 2016, New Orleans, LO (USA)
06/10/2016
“Pharmacodynamic (PD) Profile of BioChaperone® Combo (BC Combo), a New Combination of Rapid-Acting and Long-Acting Insulin, in Subjects with Type 2 Diabetes Mellitus (T2DM)” (Poster 942), presented by Dr. Simon Bruce, 76th Scientific Sessions American Diabetes Association 11-13 June 2016, New Orleans, LO (USA)
06/08/2016
Adocia reinforces its focus on diabetes with the launch of a new project: BioChaperone Glucagon
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
06/06/2016
Adocia to Present Data Validating the Potential of BioChaperone® Technology at the American Diabetes Association® 76th Scientific Sessions
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
05/31/2016
Adocia and Lilly announce positive topline results from a Phase 1 study evaluating ultra-rapid insulin BioChaperone Lispro U100 in healthy Japanese subjects
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
04/27/2016
Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro U100 in people with type 2 diabetes
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
04/11/2016
Adocia Initiates a Phase 1/2 Clinical Trial on the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
03/21/2016
Adocia Welcomes Internationally Renowned Diabetes Experts to Inaugural Medical Advisory Board
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
03/14/2016
Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
Join our mailing list. Subscribe